Mechelen, Belgium; 22 December 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Wellington Management Group LLP.
Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 17 December 2015 from Wellington Management Group LLP, who notified that, as a result of an acquisition of shares, since 3 December 2015, its entirely-controlled subsidiary Wellington Management Company LLP held 1,989,368 shares, representing 5.1% of the current 39,076,342 outstanding Galapagos shares. Wellington Management Group LLC thus crossed a 5% threshold of Galapagos’ voting rights. This is the first transparency notice received from Wellington Management Group LLP. The full transparency notice is available for viewing on the Galapagos website.
About Galapagos
Galapagos(Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises three Phase 2, three Phase 1, five pre-clinical, and 20 discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We are focused on the development and commercialization of novel medicines that will improve people’s lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
